Annual CFF
-$11.90 M
-$87.30 M-115.78%
31 December 2023
Summary:
United Therapeutics annual cash flow from financing activities is currently -$11.90 million, with the most recent change of -$87.30 million (-115.78%) on 31 December 2023. During the last 3 years, it has fallen by -$56.70 million (-126.56%). UTHR annual CFF is now -101.95% below its all-time high of $611.20 million, reached on 31 December 2019.UTHR Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
-$64.10 M
-$16.10 M-33.54%
30 September 2024
Summary:
United Therapeutics quarterly cash flow from financing activities is currently -$64.10 million, with the most recent change of -$16.10 million (-33.54%) on 30 September 2024. Over the past year, it has increased by +$28.70 million (+30.93%). UTHR quarterly CFF is now -107.92% below its all-time high of $809.10 million, reached on 31 March 2019.UTHR Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
-$1.27 B
-$71.70 M-5.97%
30 September 2024
Summary:
United Therapeutics TTM cash flow from financing activities is currently -$1.27 billion, with the most recent change of -$71.70 million (-5.97%) on 30 September 2024. Over the past year, it has dropped by -$1.26 billion (-10596.64%). UTHR TTM CFF is now -256.76% below its all-time high of $812.00 million, reached on 30 June 2019.UTHR TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
UTHR Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | +30.9% | -10000.0% |
| 3 y3 years | -126.6% | -954.7% | -2941.3% |
| 5 y5 years | -102.0% | +57.3% | -308.3% |
UTHR Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -115.8% | at low | -215.5% | +94.0% | -1033.2% | at low |
| 5 y | 5 years | -102.0% | +29.6% | -215.5% | +94.0% | -308.3% | at low |
| alltime | all time | -102.0% | +97.9% | -107.9% | +94.0% | -256.8% | at low |
United Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$64.10 M(+33.5%) | -$1.27 B(+6.0%) |
| June 2024 | - | -$48.00 M(-95.5%) | -$1.20 B(+6.4%) |
| Mar 2024 | - | -$1.07 B(+1050.9%) | -$1.13 B(+9383.2%) |
| Dec 2023 | -$11.90 M(-115.8%) | -$92.80 M(-1321.1%) | -$11.90 M(-108.7%) |
| Sept 2023 | - | $7.60 M(-69.2%) | $136.40 M(+0.4%) |
| June 2023 | - | $24.70 M(-49.2%) | $135.80 M(+0.6%) |
| Mar 2023 | - | $48.60 M(-12.4%) | $135.00 M(+79.0%) |
| Dec 2022 | $75.40 M(+68.3%) | $55.50 M(+692.9%) | $75.40 M(+175.2%) |
| Sept 2022 | - | $7.00 M(-70.7%) | $27.40 M(-25.9%) |
| June 2022 | - | $23.90 M(-317.3%) | $37.00 M(+56.1%) |
| Mar 2022 | - | -$11.00 M(-246.7%) | $23.70 M(-47.1%) |
| Dec 2021 | $44.80 M(-365.1%) | $7.50 M(-54.8%) | $44.80 M(+3.2%) |
| Sept 2021 | - | $16.60 M(+56.6%) | $43.40 M(+34.0%) |
| June 2021 | - | $10.60 M(+5.0%) | $32.40 M(-25.3%) |
| Mar 2021 | - | $10.10 M(+65.6%) | $43.40 M(-356.8%) |
| Dec 2020 | -$16.90 M(-102.8%) | $6.10 M(+8.9%) | -$16.90 M(-90.2%) |
| Sept 2020 | - | $5.60 M(-74.1%) | -$173.00 M(-23.8%) |
| June 2020 | - | $21.60 M(-143.0%) | -$226.90 M(-8.5%) |
| Mar 2020 | - | -$50.20 M(-66.5%) | -$248.10 M(-140.6%) |
| Dec 2019 | $611.20 M(+9601.6%) | -$150.00 M(+210.6%) | $611.20 M(-19.7%) |
| Sept 2019 | - | -$48.30 M(<-9900.0%) | $761.30 M(-6.2%) |
| June 2019 | - | $400.00 K(-100.0%) | $812.00 M(+0.9%) |
| Mar 2019 | - | $809.10 M(>+9900.0%) | $804.80 M(>+9900.0%) |
| Dec 2018 | $6.30 M(-85.5%) | $100.00 K(-95.8%) | $6.30 M(-21.3%) |
| Sept 2018 | - | $2.40 M(-135.3%) | $8.00 M(-12.1%) |
| June 2018 | - | -$6.80 M(-164.2%) | $9.10 M(-53.3%) |
| Mar 2018 | - | $10.60 M(+488.9%) | $19.50 M(-55.0%) |
| Dec 2017 | $43.30 M(-108.7%) | $1.80 M(-48.6%) | $43.30 M(-171.9%) |
| Sept 2017 | - | $3.50 M(-2.8%) | -$60.20 M(-69.3%) |
| June 2017 | - | $3.60 M(-89.5%) | -$196.00 M(-42.4%) |
| Mar 2017 | - | $34.40 M(-133.8%) | -$340.10 M(-31.7%) |
| Dec 2016 | -$497.70 M(+11.3%) | -$101.70 M(-23.1%) | -$497.70 M(+21.4%) |
| Sept 2016 | - | -$132.30 M(-5.8%) | -$409.80 M(+28.3%) |
| June 2016 | - | -$140.50 M(+14.0%) | -$319.40 M(-24.8%) |
| Mar 2016 | - | -$123.20 M(+792.8%) | -$424.60 M(-5.0%) |
| Dec 2015 | -$447.00 M(-22.5%) | -$13.80 M(-67.1%) | -$447.00 M(-33.5%) |
| Sept 2015 | - | -$41.90 M(-82.9%) | -$672.54 M(-4.4%) |
| June 2015 | - | -$245.70 M(+68.8%) | -$703.22 M(+9.8%) |
| Mar 2015 | - | -$145.60 M(-39.2%) | -$640.28 M(+11.0%) |
| Dec 2014 | -$576.60 M(>+9900.0%) | -$239.34 M(+229.8%) | -$576.60 M(+75.6%) |
| Sept 2014 | - | -$72.58 M(-60.3%) | -$328.37 M(+36.0%) |
| June 2014 | - | -$182.76 M(+123.1%) | -$241.41 M(+175.2%) |
| Mar 2014 | - | -$81.92 M(-1021.9%) | -$87.73 M(+1615.1%) |
| Dec 2013 | -$5.12 M(-97.0%) | $8.89 M(-38.2%) | -$5.12 M(-92.0%) |
| Sept 2013 | - | $14.39 M(-149.5%) | -$63.99 M(-43.5%) |
| June 2013 | - | -$29.08 M(-4290.6%) | -$113.33 M(-33.6%) |
| Mar 2013 | - | $694.00 K(-101.4%) | -$170.57 M(+0.8%) |
| Dec 2012 | -$169.14 M(-22.4%) | -$49.99 M(+43.0%) | -$169.14 M(-54.0%) |
| Sept 2012 | - | -$34.95 M(-59.5%) | -$367.67 M(+10.6%) |
| June 2012 | - | -$86.33 M(-4156.9%) | -$332.29 M(+42.1%) |
| Mar 2012 | - | $2.13 M(-100.9%) | -$233.90 M(+7.3%) |
| Dec 2011 | -$218.08 M | -$248.51 M(<-9900.0%) | -$218.08 M(-331.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2011 | - | $421.00 K(-96.5%) | $94.04 M(-11.1%) |
| June 2011 | - | $12.06 M(-32.8%) | $105.81 M(-10.0%) |
| Mar 2011 | - | $17.95 M(-71.8%) | $117.62 M(-19.9%) |
| Dec 2010 | $146.76 M(+302.3%) | $63.60 M(+421.5%) | $146.76 M(+56.3%) |
| Sept 2010 | - | $12.20 M(-48.9%) | $93.88 M(-5.9%) |
| June 2010 | - | $23.87 M(-49.3%) | $99.73 M(+20.9%) |
| Mar 2010 | - | $47.09 M(+338.8%) | $82.52 M(+126.2%) |
| Dec 2009 | $36.48 M(-82.9%) | $10.73 M(-40.5%) | $36.48 M(-80.0%) |
| Sept 2009 | - | $18.04 M(+170.9%) | $182.24 M(-5.6%) |
| June 2009 | - | $6.66 M(+538.6%) | $193.06 M(-4.1%) |
| Mar 2009 | - | $1.04 M(-99.3%) | $201.25 M(-5.5%) |
| Dec 2008 | $213.03 M(+920.3%) | $156.50 M(+442.3%) | $213.03 M(+86.9%) |
| Sept 2008 | - | $28.86 M(+94.3%) | $113.98 M(+18.7%) |
| June 2008 | - | $14.85 M(+15.8%) | $96.04 M(+6.2%) |
| Mar 2008 | - | $12.82 M(-77.7%) | $90.43 M(+333.1%) |
| Dec 2007 | $20.88 M(-71.8%) | $57.46 M(+426.5%) | $20.88 M(-69.3%) |
| Sept 2007 | - | $10.91 M(+18.1%) | $68.09 M(+229.8%) |
| June 2007 | - | $9.24 M(-116.3%) | $20.65 M(+48.8%) |
| Mar 2007 | - | -$56.73 M(-154.2%) | $13.87 M(-81.3%) |
| Dec 2006 | $74.13 M(+423.1%) | $104.67 M(-386.5%) | $74.13 M(-371.8%) |
| Sept 2006 | - | -$36.53 M(-1584.6%) | -$27.28 M(-290.3%) |
| June 2006 | - | $2.46 M(-30.3%) | $14.33 M(-6.0%) |
| Mar 2006 | - | $3.53 M(+8.1%) | $15.24 M(+7.6%) |
| Dec 2005 | $14.17 M(+124.4%) | $3.27 M(-35.6%) | $14.17 M(+5.5%) |
| Sept 2005 | - | $5.07 M(+50.7%) | $13.43 M(+17.9%) |
| June 2005 | - | $3.37 M(+36.9%) | $11.39 M(+28.3%) |
| Mar 2005 | - | $2.46 M(-2.7%) | $8.88 M(+40.6%) |
| Dec 2004 | $6.32 M(+214.7%) | $2.53 M(-16.6%) | $6.32 M(+176.2%) |
| Sept 2004 | - | $3.03 M(+253.8%) | $2.29 M(+418.6%) |
| June 2004 | - | $857.00 K(-940.2%) | $441.00 K(-76.9%) |
| Mar 2004 | - | -$102.00 K(-93.2%) | $1.91 M(-4.9%) |
| Dec 2003 | $2.01 M(+984.9%) | -$1.50 M(-226.5%) | $2.01 M(-43.2%) |
| Sept 2003 | - | $1.19 M(-49.0%) | $3.53 M(+39.7%) |
| June 2003 | - | $2.32 M(<-9900.0%) | $2.53 M(+1152.0%) |
| Mar 2003 | - | -$3000.00(-112.0%) | $202.00 K(+9.2%) |
| Dec 2002 | $185.00 K(-106.4%) | $25.00 K(-86.3%) | $185.00 K(+35.7%) |
| Sept 2002 | - | $183.00 K(-6200.0%) | $136.30 K(-133.2%) |
| June 2002 | - | -$3000.00(-85.0%) | -$410.10 K(-78.3%) |
| Mar 2002 | - | -$20.00 K(-15.6%) | -$1.89 M(-34.4%) |
| Dec 2001 | -$2.88 M(-101.4%) | -$23.70 K(-93.5%) | -$2.88 M(-58.6%) |
| Sept 2001 | - | -$363.40 K(-75.5%) | -$6.96 M(-105.4%) |
| June 2001 | - | -$1.48 M(+46.9%) | $127.82 M(-2.1%) |
| Mar 2001 | - | -$1.01 M(-75.4%) | $130.60 M(-36.8%) |
| Dec 2000 | $206.61 M(+248.4%) | -$4.10 M(-103.1%) | $206.61 M(-1.7%) |
| Sept 2000 | - | $134.41 M(>+9900.0%) | $210.12 M(+149.2%) |
| June 2000 | - | $1.30 M(-98.3%) | $84.30 M(-36.4%) |
| Mar 2000 | - | $75.00 M(<-9900.0%) | $132.50 M(+123.4%) |
| Dec 1999 | $59.30 M(+159.0%) | -$600.00 K(-107.0%) | $59.30 M(-1.0%) |
| Sept 1999 | - | $8.60 M(-82.6%) | $59.90 M(+16.8%) |
| June 1999 | - | $49.50 M(+2650.0%) | $51.30 M(+2750.0%) |
| Mar 1999 | - | $1.80 M | $1.80 M |
| Dec 1998 | $22.90 M | - | - |
FAQ
- What is United Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for United Therapeutics?
- What is United Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for United Therapeutics?
- What is United Therapeutics quarterly CFF year-on-year change?
- What is United Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for United Therapeutics?
- What is United Therapeutics TTM CFF year-on-year change?
What is United Therapeutics annual cash flow from financing activities?
The current annual CFF of UTHR is -$11.90 M
What is the all time high annual CFF for United Therapeutics?
United Therapeutics all-time high annual cash flow from financing activities is $611.20 M
What is United Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of UTHR is -$64.10 M
What is the all time high quarterly CFF for United Therapeutics?
United Therapeutics all-time high quarterly cash flow from financing activities is $809.10 M
What is United Therapeutics quarterly CFF year-on-year change?
Over the past year, UTHR quarterly cash flow from financing activities has changed by +$28.70 M (+30.93%)
What is United Therapeutics TTM cash flow from financing activities?
The current TTM CFF of UTHR is -$1.27 B
What is the all time high TTM CFF for United Therapeutics?
United Therapeutics all-time high TTM cash flow from financing activities is $812.00 M
What is United Therapeutics TTM CFF year-on-year change?
Over the past year, UTHR TTM cash flow from financing activities has changed by -$1.26 B (-10596.64%)